Feedback
Settings

Settings

Goto Application

26,628 results
Offices all Languages Stemming false Single Family Member true Include NPL false

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:C12N7/00

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1 / 2,663
1.20210315951CANCER THERAPY BY COMBINATION USE OF ONCOLYTIC VACCINIA VIRUS AND IMMUNE CHECKPOINT INHIBITOR, AND PHARMACEUTICAL COMPOSITION AND COMBINATION MEDICINE FOR USE IN THE CANCER THERAPY
US - 14.10.2021
Int.Class A61K 35/768
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
66Microorganisms or materials therefrom
76Viruses; Subviral particles; Bacteriophages
768Oncolytic viruses not provided for in groups A61K35/761-A61K35/76697
 Appl.No 17279937 Applicant ASTELLAS PHARMA INC. Inventor Shinsuke NAKAO

The present invention provides a combination therapy of genetically modified vaccinia virus (particularly oncolytic vaccinia virus) and another cancer therapy for use in treating cancer, and a pharmaceutical composition and a combination kit for use in the therapy. More specifically, the invention provides a therapy with vaccinia virus containing a polynucleotide encoding interleukin-7 (IL-7) and a polynucleotide encoding interleukin-12 (IL-12) in combination with an immune checkpoint inhibitor, and a pharmaceutical composition and a combination kit for use in the therapy.

2.20210315989METHODS TO PREPARE NASOPHARYNGEAL AND ORAL MATERIAL FOR ORAL INOCULATION OF COVID-19
US - 14.10.2021
Int.Class A61K 39/215
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
215Coronaviridae, e.g. avian infectious bronchitis virus
 Appl.No 17223920 Applicant Steven Mark Hayden Inventor Steven Mark Hayden

The instant disclosure relates generally to oral inoculation and specifically to methods to prepare nasopharyngeal and oral material for oral inoculation of COVID-19. Severe acute respiratory syndrome coronavirus 2 (“SARS-CoV-2”) viral particles are collected from at least one of a nasopharyngeal specimen and an oral specimen each derived from a patient infected with SARS-CoV-2 or a SARS-CoV-2 variant. Mammalian cells (e.g., Vero-E6 and/or Vero-CCL81 cells) are infected with the SARS-CoV-2 viral particles to produce infected mammalian cells. The infected mammalian cells are cultured to produce a mammalian cell culture. SARS-CoV-2 viral particles are collected from the mammalian cell culture to produce isolated viral particles. The isolated viral particles are frozen to produce a frozen isolate. The frozen isolate is partitioned into a plurality of tablets each having a therapeutically effective amount of the SARS-CoV-2 viral particles. An enteric coating is applied to each tablet.

3.20210316015COMPOSITIONS AND METHODS FOR THE TREATMENT OF HEART DISEASE
US - 14.10.2021
Int.Class A61K 48/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
48Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
 Appl.No 17273805 Applicant Icahn School of Medicine at Mount Sinai Inventor Hina W. Chaudhry

The disclosure relates to compositions and methods for promoting cardiomyocyte cytokinesis and cardiomyocyte proliferation and for use in cardiac regenerative therapy. Embodiments of the disclosure are particularly useful for promoting cytokinesis in adult cardiomyocytes. In embodiments, the disclosure relates to the expression of human cyclin A2 (CCNA2) under the control of a cardiac Troponin T (cTNT) promoter to promote cytokinesis of adult human cardiomyocytes.

4.WO/2021/207306RECOMBINANT BACTERIA FOR USE AS A VACCINE TO PREVENT COVID19 INFECTION
WO - 14.10.2021
Int.Class A61K 39/12
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
 Appl.No PCT/US2021/026106 Applicant SYNLOGIC OPERATING COMPANY, INC. Inventor GAO, Jian-Rong
Modified microorganisms, pharmaceutical compositions thereof, and methods of preventing and treating the coronavirus disease 2019 (COVID-19) are disclosed.
5.WO/2021/205042Composition and method for inactivating a virus
WO - 14.10.2021
Int.Class C12N 7/06
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
7Viruses, e.g. bacteriophages; Compositions thereof; Preparation or purification thereof
04Inactivation or attenuation; Producing viral sub-units
06by chemical treatment
 Appl.No PCT/EP2021/059465 Applicant GOLDSBOROUGH, Andrew Simon Inventor GOLDSBOROUGH, Andrew Simon
Provided is the use of a composition to inactive a virus. The composition comprises a quaternary ammonium compound and a halogenated organic compound. Also provided are a composition and kit for inactivating a virus, and a method for detecting an analyte in a sample.
6.WO/2021/205177APPARATUS AND METHOD FOR STERILISATION OF PATHOGENS
WO - 14.10.2021
Int.Class A61L 2/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION, OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS, OR SURGICAL ARTICLES
2Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
 Appl.No PCT/GB2021/050867 Applicant M SQUARED LASERS LIMITED Inventor MALCOLM, Graeme Peter Alexander
A laser system and method for generating a continuous-wave, tuneable optical output field having a wavelength between 200 nm and 300 nm is disclosed. The laser system comprising: a continuous-wave, narrow-linewidth, tuneable optical field source employed to generate a first output field. The first output field is arranged to propagate thorough the first enhancement cavity frequency double to generate a first frequency doubled output field. The first frequency doubled output field is then arranged to propagate thorough a second enhancement cavity frequency double to generate a second frequency doubled output field which acts as an output field for the laser system. The laser system thus provides a frequency-agile, high power and spectrally pure light source across the UVC the region of the electromagnetic spectrum which makes it a flexible and efficient source for the sterilisation or decontamination of pathogens.
7.WO/2021/205462MODIFIED GENOMES AND USE THEREOF
WO - 14.10.2021
Int.Class C12N 7/00
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
7Viruses, e.g. bacteriophages; Compositions thereof; Preparation or purification thereof
 Appl.No PCT/IL2021/050412 Applicant SYNVACCINE LTD. Inventor TULLER, Tamir
Modified genomes of an organism comprising at least one coding sequence comprising at least one mutation, wherein the mutation generates an underrepresented sequence that is underrepresented in the unmodified genome of the organism are provided. Organism and cells comprising the modified genomes of the invention, pharmaceutical compositions comprising the organisms and cells of the invention, as well as methods of making the modified genomes are also provided.
8.WO/2021/206587SARS-COV-2 DNA VACCINE BASED ON GENE THERAPY DNA VECTOR GDTT1.8NAS12
WO - 14.10.2021
Int.Class A61K 39/215
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
215Coronaviridae, e.g. avian infectious bronchitis virus
 Appl.No PCT/RU2021/000148 Applicant GENETIC DIAGNOSTICS AND THERAPY 21 LTD Inventor GAMOLSKI, Anton
The invention refers to genetic engineering and can be used in biotechnology, medicine as a DNA vaccine for human vaccination against SARS-CoV-2 virus. A DNA vaccine as a composition of gene therapy DNA vectors GDTT1.8NAS12-S, GDTT1.8NAS12-M, and GDTT1.8NAS12-N based on gene therapy DNA vector GDTT1.8NAS12 encoding immunogenic epitopes of S, M, and N proteins of SARS-CoV-2 virus was constructed. Each of the constructed gene therapy DNA vectors included in the DNA vaccine has the ability to efficiently penetrate human and animal cells and express the therapeutic S protein of SARS-CoV-2 cloned to it, therapeutic M protein of SARS-CoV-2 cloned to it and therapeutic N protein of SARS- CoV-2 cloned to it due to the limited size of GDTT1.8NAS12 vector part not exceeding 2600 bp. As part of each of the constructed gene therapy DNA vectors uses nucleotide sequences that are not antibiotic resistance genes or regulatory elements of viral genomes are used as the structural elements, which ensures its safe use for gene therapy and human vaccination.
9.WO/2021/207082METHOD FOR TREATING IMPLANTABLE DEVICE INFECTIONS
WO - 14.10.2021
Int.Class A61K 35/76
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
66Microorganisms or materials therefrom
76Viruses; Subviral particles; Bacteriophages
 Appl.No PCT/US2021/025794 Applicant ADAPTIVE PHAGE THERAPEUTICS, INC. Inventor BASU, Subhendu
The invention relates to the field of phage therapy and is particularly directed at providing a phage-based composition and method for treating or preventing infections associated with implantable devices. The composition may be directly administered to the infected location of the device, optionally as a single dose, and/or by other modes of administrations, and may potentially avoid any requirement for replacing the implantable device.
10.WO/2021/207730VACCINES FOR CORONAVIRUS AND METHODS OF USING THE SAME
WO - 14.10.2021
Int.Class A61K 39/215
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
215Coronaviridae, e.g. avian infectious bronchitis virus
 Appl.No PCT/US2021/026864 Applicant THE WISTAR INSTITUTE OF ANATOMY & BIOLOGY Inventor KULP, Daniel, W.
Disclosed are compositions comprising an expressible nucleic acid sequence comprising a first nucleic acid sequence comprising a sequence that encodes a self-assembling polypeptide or a pharmaceutically acceptable salt thereof and a second nucleic acid sequence comprising a sequence that encodes an antigen from a virus from the family of Coronaviridae. In some embodiments, the expressible nucleic acid sequence further comprises a nucleic acid sequence encoding at least one viral antigen or a pharmaceutically acceptable salt thereof. In some embodiments, the expressible nucleic acid sequence further comprises at least one nucleic acid sequence encoding a linker.
# -